Trump Announces Phased Tariffs on Generic Drugs Starting 2028 to Force Onshore Manufacturing
Key Insights
President Trump announced generic drugs will remain tariff-free until August 1, 2028, after which a 100% levy takes effect, escalating to 200% in August 2029.
The phased tariff schedule is designed to pressure generic drugmakers to build manufacturing plants and facilities in the United States during the two-year grace period.
Patented and branded drugs remain unchanged under the existing 100% Section 232 tariff, while major drugmakers including Eli Lilly, Pfizer, and Novo Nordisk have secured three-year tariff exemptions through "most favored nation" pricing agreements.
President Donald Trump announced on Tuesday a new package of tariffs targeting generic drugs manufactured overseas, establishing a phased schedule that begins with a two-year duty-free window before escalating to a 100% levy in August 2028 and 200% one year later.
The announcement, made via a social media post, represents a significant shift in trade policy affecting the pharmaceutical supply chain. Generic drugs imported into the United States will continue to enter tariff-free until August 1, 2028, when a 100% tariff would be imposed "for a one year period of time, and 200% thereafter," according to Trump's statement.
The president described the escalation as "a penalty" for companies that fail to build plants and facilities in the U.S. within the grace period, explicitly framing the policy as a mechanism to coerce drugmakers into moving production onshore.
Policy Context and Reversal
The new tariff announcement comes just three months after Trump issued a proclamation stating that generic pharmaceuticals "are not subject to tariffs at this time," while noting that the decision "will be reassessed in one year." This latest move marks what observers have characterized as a head-spinning reversal on tariff policy.
Tariffs on patented and branded drugs remain unchanged under the existing framework. The president imposed a 100% levy on patented pharmaceutical products and ingredients under Section 232 on April 2, while exempting generic drugs, biosimilars, and related ingredients. Larger drugmakers were given 120 days before the 100% tariff rate goes into effect, and smaller drugmakers, which rely on contract manufacturers, had 180 days before that rate takes effect.
Industry Impact and Exemptions
More than a dozen major drugmakers, including Eli Lilly, Pfizer, and Novo Nordisk, have struck deals with the Trump administration to lower the prices of new and existing medicines. Those agreements are part of the president's "most favored nation" policy, which ties U.S. drug prices to cheaper ones abroad and exempts the participating companies from tariffs for three years.
Trump has consistently used tariff threats and his most-favored-nation pricing policy to press drugmakers into charging Americans no more than patients in other high-income countries.
Legal and Political Questions
Trump did not state what legal authority he was claiming to impose future tariffs on generic drugs. The projected 200% tariff, which would come into effect in August 2029, would take effect six months after the end of his final term, raising questions about the enforceability of such a future commitment.
The announcement has drawn criticism from Democratic lawmakers, who have pledged to repeal Trump's tariffs if they regain control of Congress. Congressman Ted Lieu, a California Democrat, stated: "Democrats will flip the House. And on Day 1 of next term, Democrats will introduce legislation to repeal Trump's disastrous tariffs. And we will pass it."
Senator Ron Wyden, an Oregon Democrat, characterized the broader tariff approach as "yet another shakedown that will raise the cost-of-living for Americans, their families, and small businesses across the country," adding that he would introduce legislation to "rein him in and put Congress back in the driver's seat."